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Abstract
The Notch signaling pathway is a critical component of vascular formation and morphogenesis in
both development and disease. Compelling evidence indicates that Notch signaling is required for
the induction of arterial-cell fate during development and for the selection of endothelial tip and
stalk cells during sprouting angiogenesis. In mammals, two of the four Notch receptors (Notch1
and Notch4) and three of the five Notch ligands (Jagged1, Dll1, and Dll4) are predominantly
expressed in vascular endothelial cells and are important for many aspects of vascular biology.
During arterial cell-fate selection and angiogenesis, the roles of Notch1 and Notch4 are thought to
be similar, and the function of Dll4 is well-characterized. However, the molecular mechanisms that
determine the functional similarities and differences of Notch ligands in vascular endothelial cells
remain largely unknown; consequently, additional research is needed to elucidate the ligand-specific
functions and mechanisms associated with Notch activation in the vascular endothelium. Results
from recent studies indicate that Dll1 and Dll4 have distinct roles in the specification and
maintenance of arterial cell identity, while Dll4 and Jagged1 have opposing functions in tip- and
stalk-cell selection during sprouting angiogenesis. This review will focus on the newly discovered,
distinct functions of several Notch ligands in the regulation of blood vessel formation and will
provide perspectives for future research in the field.
Introduction
Notch signaling is evolutionarily conserved and critical
for cell-fate determination, differentiation, and many
other biological processes [1]. The mammalian Notch sig-
naling pathway is composed of four Notch receptors
(Notch1-4) and five ligands (Jagged1 and 2 and Delta-like
[Dll] 1, 3, and 4). All of the ligands are transmembrane-
type proteins and, consequently, Notch signaling is often
mediated by cell-cell interactions. Transmission generally
occurs between neighboring cells that express high levels
of either the receptor or the ligand, although receptor-lig-
and coexpression occurs in some cells, such as vascular
endothelial cells. Over the last decade, numerous studies
have demonstrated that Notch signaling is critically
involved in vascular development and disease [2-6]. For
example, Notch signaling is required for arterial cell-fate
determination during embryonic development, and the
Notch pathway controls both developmental and patho-
logical angiogenesis by modulating the selection of
endothelial tip and stalk cells in newly sprouting blood
vessels. Regulation of the Notch pathway in blood vessels
has been well characterized; however, the specific roles of
each Notch ligand during vascular formation and mor-
phogenesis are unknown. Recent studies provide insight
into the distinct functions of Notch ligands in blood ves-
sels, and this review summarizes the current understand-
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ing of how several ligands differentially activate Notch
signaling in the vasculature.
Basic mechanisms of the Notch signaling 
pathway
Notch signaling is initiated by interactions between a
Notch ligand expressed on the surface of one cell (the sig-
naling cell) and a Notch receptor expressed on the surface
of a neighboring cell (the receiving cell). Upon ligand
binding, Notch is sequentially cleaved, and the Notch
intracellular domain (NICD) is released into the cyto-
plasm. The NICD enters the nucleus, where it interacts
with the transcription factor CSL (named after mamma-
lian CBF1, Drosophila Su(H), and Caenorhabditis elegans
LAG1) to form a transcriptional activation complex that
induces expression of the bHLH transcription factors (Hes
and Hey families) (Figure 1). This signaling mechanism is
considered the "canonical" Notch pathway; non-canoni-
cal Notch signaling has also been reported [7].
The extracellular domains of mammalian Notch ligands
have several distinct features that participate in receptor
binding (Figure 2). Their N-terminal regions contain a
conserved module, and a second conserved module, the
DSL (Delta/Serrate/LAG-2) domain, is located adjacent to
the N-terminal region. Both Notch ligands and receptors
contain multiple EGF-like repeats, and the ligands
Jagged1, Jagged2, and Dll1 have tandem EGF repeats that
form the DOS (Delta and OSM-11-like proteins) domain
[8]. Jagged1 and Jagged2 also contain a cysteine-rich
domain located between the EGF-like repeats and the
transmembrane domain. Both the DSL and DOS domains
are critical for receptor binding [9], and the structural
diversity of Notch ligands is determined by the presence
or absence of the cysteine-rich DOS domains.
Activation of Notch signaling through cell-cell interac-
tions (trans-interactions) has been well characterized;
however, Notch ligands also regulate the Notch pathway
by binding to Notch receptors within the same cell (cis-
interactions) [10,11]. In general, trans-interactions
between Notch ligands and receptors activate Notch sign-
aling, whereas cis-interactions are believed to inhibit
Notch signaling [9]. The precise mechanisms that mediate
Notch activation by the cis-interactions remain unclear,
and further studies need to be performed [12].
Notch receptor and ligand expression in blood 
vessels
Notch1 is broadly expressed in many tissues, including
the heart and vascular endothelial cells, while Notch4
expression is restricted to vascular endothelial cells [13-
15], and Notch3 is predominantly expressed in vascular
smooth muscle cells [16]. Transcriptional regulation of
A diagram of the canonical Notch signaling pathway Figure 1
A diagram of the canonical Notch signaling pathway. 
This schematic shows a simplified overview of the main com-
ponents of Notch signaling. Upon Notch ligand binding, a 
two-step proteolysis cleavage process (small arrows) within 
the juxtamembrane region and transmembrane domain of 
the Notch receptor is catalyzed by a member of the disin-
tegrin and metalloproteases (ADAMS) family and the γ-
secretase containing complex, respectively, then the Notch 
intracellular domain (NICD) is released from the membrane 
and translocates to the nucleus, where it forms a transcrip-
tional activation complex with CSL and coactivators (CoA), 
thereby inducing the transcription of target genes.
Domain organization of mammalian Notch ligands Figure 2
Domain organization of mammalian Notch ligands. 
Five mammalian ligands are classified into two categories, 
Delta-like (Dll1, Dll3, Dll4) and Serrate-like (Jagged1, 
Jagged2), based on structural homology to the two Dro-
sophila ligands, Delta and Serrate. All Notch ligands have an 
N-terminal domain, a DSL (Delta/Serrate/LAG-2) domain 
and EGF-like repeats. Jagged1 and Jagged2 contain a cysteine-
rich domain, whereas Jagged1, Jagged2, and Dll1 have two 
DOS (Delta and OSM-11-like proteins) domains located 
immediately following the DSL domain.Journal of Angiogenesis Research 2009, 1:8 http://www.jangiogenesis.com/content/1/1/8
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Notch4  in vascular endothelial cells is controlled by
fibroblast growth factor 2 (FGF2), the signal-dependent
transcription-factor activator protein 1 (AP-1), and the
glucocorticoid receptor [14,15,17]. Four of the five known
mammalian Notch ligands (Jagged1, Jagged2, Dll1, and
Dll4) are expressed in vascular endothelial cells [13,18-
20]; Jagged1 is also expressed in smooth muscle cells sur-
rounding the arteries and plays an important role in
smooth muscle cell maturation [21]. The molecular
mechanisms that control the expression of Notch ligands
in vascular endothelial cells and smooth muscle cells have
been frequent topics of recent research (Table 1). For
example, Dll4 expression during arterial specification and
for tip-cell selection during vessel sprouting [22-28] is
mediated by vascular endothelial growth factor (VEGF).
Importantly, and as described below, the expression pat-
terns of the Notch ligands vary both spatially and tempo-
rally and, consequently, the localization of each ligand is
likely to be critical for Notch activation in blood vessels
(Figures 3, 4, 5, 6, and 7).
Notch1, Notch4, and the ligands Dll1 and Dll4 
during arterial specification and maintenance
Results from recent studies in zebrafish suggest that acti-
vation of Notch signaling by the Sonic hedgehog (Shh)
and VEGF pathways is essential for arterial specification
during development [29,30]. Two Notch receptors,
Notch1 and Notch4, are predominantly expressed in arte-
rial endothelial cells of early mouse embryos. Notch1
mutant mice die with cardiovascular defects during early
development [13], and endothelial-specific ablation of
Notch1 in mice leads to embryonic lethality and vascular
abnormalities that are associated with angiogenesis [31].
An endothelial-specific Notch1+/- mutation has also been
associated with impaired postnatal neovascularization in
a marine hind-limb ischemia model [32]. These results
demonstrate the cell-type specific role of Notch1 in the
vascular endothelium during development and postnatal
life (Table 2). Notch4 mutant mice display no conspicu-
ous phenotype, but the vascular defects observed in com-
pound Notch1; Notch4 mutant embryos are more severe
than those in Notch1 mutants [13], which suggests that
the functions of Notch1 and Notch4 overlap during vas-
cular development. Endothelial expression of a constitu-
tively active Notch4 mutant from the Flk1 (VEGFR2) locus
results in embryonic vascular abnormalities such as disor-
ganized vascular networks and dilated blood vessels [33],
and in adult mice, constitutively active Notch4 expression
has been associated with arteriovenous malformations
(AVMs) (i.e., abnormal connections between arteries and
veins) that are accompanied by ectopic expression of the
arterial marker ephrinB2 in veins [34]. Furthermore, the
Arterial cell specification mediated by Dll4-Notch signaling Figure 3
Arterial cell specification mediated by Dll4-Notch 
signaling. During early development, VEGF (in concert with 
Foxc1/c2 transcription factors) induces Dll4 expression in 
endothelial cells, and Dll4-Notch signaling promotes arterial 
gene expression.
Table 1: Signaling pathways/factors that regulate Notch ligand expression in vascular endothelial and smooth muscle cells
Pathway/factor Ligand Cell type Biological effect References
VEGF Dll4 (↑) Endothelial cells Arterial specification [22,24,27]
Endothelial tip cell formation in sprouting 
angiogenesis
[23,25,26,28]
TNFα Dll4 (↓) Jagged1 (↑) Endothelial cells Tip cell and stalk cell selection [52]
VEGF + FGF2
(synergistic)
Dll1 (↑) Endothelial cells Ischemia-induced postnatal arteriogenesis [38]
PDGF/angiotensin II Jagged1 (↓) Smooth muscle cells Growth regulation [45]
Jagged1 (endothelial) Jagged1 (↑) Mural cells Smooth muscle cell maturation [21]
↑, Upregulation; ↓, Downregulation.
VEGF, vascular endothelial growth factor; TNF, tumor necrosis factor; FGF, Fibroblast growth factor; PDGF, platelet-derived growth factorJournal of Angiogenesis Research 2009, 1:8 http://www.jangiogenesis.com/content/1/1/8
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impaired arterial and venous differentiation associated
with constitutively active Notch4 expression can be
reversed by suppressing Notch4 activity in the endothe-
lium [34]. Collectively, these findings suggest that both
reduced and elevated Notch signaling can lead to vascular
abnormalities and, consequently, that the maintenance of
proper Notch signaling is critical during vascular develop-
ment.
Of the four Notch ligands (Jagged1, Jagged2, Dll1, and
Dll4) that are expressed in arterial endothelial cells, Dll4
alone is expressed in the dorsal aorta of mice at embryonic
day 8.5 (E8.5), and its expression is restricted to vascular
endothelial cells [13]; thus, Dll4 is believed to be the lig-
and for Notch1 and Notch4 during early vascular develop-
Opposing effects of Dll4 and Jagged1 on sprouting angiogen- esis Figure 7
Opposing effects of Dll4 and Jagged1 on sprouting 
angiogenesis. VEGF signaling induces Dll4 expression in tip 
cells, and Dll4, in turn, activates Notch signaling in stalk cells, 
which reduces stalk-cell sensitivity to VEGF stimulation and, 
consequently suppresses the tip-cell phenotype. Conversely, 
Jagged1 antagonizes Dll4-mediated Notch activation in stalk 
cells to increase tip cell numbers and enhances vessel sprout-
ing. The antagonistic effects of the two ligands are controlled 
by Fringe-dependent modulation of Notch signaling.
Jagged1-mediated hematopoietic program in the dorsal aorta  during development Figure 5
Jagged1-mediated hematopoietic program in the 
dorsal aorta during development. Hematopoietic stem 
cells (HSC) descend from Jagged1+ Notch1+ endothelial 
cells in the aorta.
Maintenance of arterial identity mediated by Dll1-Notch sign- aling Figure 4
Maintenance of arterial identity mediated by Dll1-
Notch signaling. At a later stage of development, Dll1 
expression is induced in arterial endothelial cells and is 
required for maintenance of the arterial phenotype. Dll1 also 
acts upstream of VEGF by regulating the expression of 
VEGFR2 and its co-receptor neuropilin 1 (Nrp1).
Smooth-muscle maturation mediated by Jagged1/Dll1- Notch3 signaling Figure 6
Smooth-muscle maturation mediated by Jagged1/
Dll1-Notch3 signaling. Jagged1 and Dll1 in endothelial cells 
activate Notch3 on mural cells, thereby promoting mural-cell 
maturation.Journal of Angiogenesis Research 2009, 1:8 http://www.jangiogenesis.com/content/1/1/8
Page 5 of 9
(page number not for citation purposes)
ment (Figure 3). Dll4  mutant mice display early
embryonic lethality with impaired arterial specification
and AVMs that appear in a genotype-dependent manner
(i.e., the severity increases with the number of mutant
alleles) [35-37]. These observations further emphasize the
importance of maintaining proper Notch activity levels
during vascular development. Foxc1 and Foxc2 transcrip-
tion factors directly activate the Dll4 promoter in endothe-
lial cells, and their induction of Dll4  expression is
enhanced by VEGF, which suggests that Foxc1 and Foxc2
act upstream of Notch signaling during arterial-cell speci-
fication [22,27].
Dll1 expression is detected in arterial endothelial cells at a
later stage (E13.5) of mouse development [19] and con-
tinues to be restricted to arterial endothelial cells in adults
[38]. Dll1 is not critically involved in arterial-cell specifi-
cation; however, analyses in hypomorphic and endothe-
lial-specific  Dll1  mutant mice indicate that Dll1 is
required for the maintenance of arterial identity [19].
Expression of the arterial marker ephrinB2 is reduced, and
the venous marker COUP-TFII is upregulated, in endothe-
lial-specific Dll1 mutant mice, despite Dll4 expression in
the mutant endothelial cells [19]; thus, Dll4 appears to be
essential for initiating the arterial program, whereas Dll1
is required to maintain arterial identity during embryonic
development. In addition, Sorensen et al. have shown that
Dll1-mediated Notch1 activation upregulates VEGF recep-
tor 2 (VEGFR2) and its coreceptor, neuropilin-1, which
suggests that Dll1 enhances the responsiveness of arterial
endothelial cells to VEGF signaling. Thus, Dll4-mediated
Notch signaling occurs downstream of VEGF during arte-
rial specification, whereas Dll1-mediated Notch signaling
acts upstream of VEGF to maintain arterial identity (Fig-
ures 3 and 4). Dll1 is also important for ischemia-induced
postnatal arteriogenesis and the induction of ephrinB2
[38].
Jagged1 does not play a critical role in arterial develop-
ment [39-41] but is required for the definitive hematopoi-
etic program in the dorsal aorta. After arterial and venous
endothelial cells differentiate, the ventral region of the
dorsal aorta, located in the aorta-gonad-mesonephros
(AGM) region of the mid-gestation mouse embryo
(around E10-11), generates the first adult hematopoietic
stem cells (HSCs). Notch4 is broadly expressed through-
out the aortic endothelium of the AGM, whereas Notch1
expression is restricted to the ventral region of the dorsal
aorta [40,42]. Importantly, three Notch ligands (Jagged1,
Jagged2, and Dll4) have distinctive expression patterns in
the dorsal aorta of the AGM: Jagged1 and Notch1 expres-
sion overlap in the dorsal aorta, Jagged2 expression occurs
in endothelial cells adjacent to Notch1-positive endothe-
lial cells, and Dll4 is expressed in both Notch1-positive
and Notch1-negative endothelial cells [40,42]. Analyses
in Jagged1 mutant mice indicate that Jagged1 is required
for Notch1 activation during the induction of intra-
embryonic definitive hematopoiesis in the AGM [40].
Jagged2 and Dll4 expression in the AGM of Jagged1
mutant embryos is normal, and hematopoiesis is normal
in Jagged2 mutant mice [40]; thus, the function of Jagged1
is distinct from Dll4 and Jagged2 activity during the
hematopoietic program of the newly formed aorta (Figure
5).
Notch3, Jagged1, and Dll1 during smooth-
muscle differentiation and maturation
Notch3 is predominantly expressed in the vascular
smooth muscle of arteries and is not expressed in veins.
Mutations in human NOTCH3 are associated with cere-
bral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL), a disorder
that causes stroke and dementia and is accompanied by
the degeneration of vascular smooth muscle cells [43];
adult Notch3 mutant mice display a defect in the matura-
tion of arterial smooth muscle cells [44]. As noted above,
Jagged1 mutant mice exhibit normal arterial development
[39,40], yet endothelial-specific Jagged1  mutants have
impaired vascular smooth muscle differentiation [39].
This observation indicates that Jagged1 expression in the
arterial endothelium activates Notch in neighboring cells,
and that this function is critical for smooth muscle cell dif-
ferentiation. Jagged1 expression by endothelial cells
induces mural cells (pericytes in the microvasculature or
smooth muscle cells in larger vessels) to express Notch3
and Jagged1, which subsequently promotes and main-
tains the differentiation phenotype of mural cells [21],
whereas platelet-derived growth factor (PDGF) and angi-
otensin II downregulate Notch3 and Jagged1 expression
in vascular smooth muscle cells [45]. Furthermore, a
recent study found that expression of the arterial smooth
muscle marker smoothelin is impaired in Dll1  mutant
mice [19], and this decline has also been observed in
Notch3-mutant arteries [44]. Taken together, these find-
ings suggest that Jagged1 and Dll1 are the primary ligands
that regulate Notch3 activity during smooth-muscle dif-
ferentiation and maturation (Figure 6).
Dll4 and Jagged1 in tip- and stalk-cell 
specification during sprouting angiogenesis
The formation of new blood vessels, a process known as
angiogenesis, involves the sprouting of endothelial cells.
In response to VEGF stimulation, filopodia extend from a
migratory endothelial cell at the vessel's tip (i.e., the tip
cell), and proliferative endothelial cells (i.e., stalk cells)
form the trunk of the new vessel. Recent studies in mice
and zebrafish clearly demonstrate that Notch signaling
interacts with VEGF signaling during tip-cell and stalk-cell
specification [5]. VEGF induces Dll4 expression in tip
cells, then Dll4 activates the Notch pathway in adjacentJournal of Angiogenesis Research 2009, 1:8 http://www.jangiogenesis.com/content/1/1/8
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endothelial cells to reduce expression of VEGFR2 and
VEGFR3, thereby suppressing the tip-cell phenotype, and
tip-cell phenotype suppression cell-autonomously pro-
motes the stalk-cell phenotype. Together, these mecha-
nisms balance tip-cell and stalk-cell selection and,
consequently, limit the number of sprouting vessels (Fig-
ure 7). Genetic or pharmacological disruption of Dll4-
Notch signaling leads to excessive tip-cell formation and
vessel sprouting in cultured cells, in zebrafish and mouse
embryos, and during tumor angiogenesis [23,25,46-51].
By using endothelial-specific Jagged1  mutant mice and
mice that overexpress Jagged1 in vascular endothelial cells,
Benedito et al. demonstrated that Jagged1 enhances ang-
iogenesis and antagonizes the effects of Dll4-mediated
Notch signaling during sprouting angiogenesis [52].
Jagged1 is strongly expressed in stalk cells, whereas Dll4 is
predominantly detected in tip cells [52], and the antago-
nistic interaction between Dll4 and Jagged1 in endothelial
cells is mediated by the glycosyltransferase Fringe, which
regulates the posttranslational modifications of Notch
receptors in a ligand-dependent manner. Fringe enhances
Notch activation in response to Delta-like ligands and
reduces Notch activity in response to Jagged ligands [12];
consequently, Fringe increases Dll4-induced endothelial
Notch signaling and reduces Notch signaling in response
to Jagged1 [52]. Jagged1 also appears to promote vascular
sprouting by regulating VEGFR3 expression in tip cells
[52]. Taken together, these results illustrate the opposing
effects of Dll4 and Jagged1 on sprouting angiogenesis.
Notch ligands in pathological angiogenesis
Dll4 is expressed in tumor vasculature [26,36,53,54], and
as observed in studies of developmental angiogenesis, the
blockade of Dll4-mediated Notch signaling (via systemic
administration of Dll4-neutralizing antibodies [47,48]
and systemic or local administration of modified Dll4
proteins [47,55]) increased tumor-vessel sprouting, which
indicates that Dll4-Notch signaling is critical for tip- and
stalk-cell selection during tumor angiogenesis. Remarka-
bly, the inhibition of Dll4-Notch signaling increased neo-
vascularization but impaired tumor growth, because the
non-productive angiogenesis reduced tumor perfusion.
Conversely, Dll4 activation of endothelial Notch signal-
ing reduces tumor angiogenesis, but increases vessel
diameter and perfusion, which enhances tumor growth
[47,56]. For these reasons, Dll4 is now recognized as a
potential therapeutic target for tumor angiogenesis [57].
As described above, Jagged1 antagonizes Dll4 during
sprouting angiogenesis [52], and overexpression of
Jagged1 in tumor cells has been shown to enhance neo-
vascularization and tumor growth [58]; however, the role
of Jagged1 in pathological angiogenesis (including tumor
angiogenesis) is not yet fully understood. Current find-
ings suggest that angiogenic sprouting in the tumor is
tightly controlled by positive and negative regulation of
Jagged1 and Dll4 in both endothelial and non-endothe-
lial cells. Recent studies have shown that a soluble form of
Notch1 (Notch decoy) acts as an antagonist of ligand-
dependent Notch signaling by (potentially) interfering
with Dll1, Dll4, and Jagged1 [59,60]. Importantly, the
Notch decoy reduces tumor growth without increasing
vessel growth, which suggests that the effects of the Notch
decoy differ from those induced by Dll4 blockade. It is
therefore likely that the proangiogenic function of
Jagged1 in tumor cells and endothelial cells could also
influence tumor angiogenesis.
Notch signaling in peripheral ischemia
Notch signaling is also required for angiogenesis in
peripheral ischemia models [32,38] (Table 2). Blood flow
recovery and postnatal neovascularization in response to
hind-limb ischemia are impaired in both global and
endothelial-specific Notch1+/- mice, but not in Notch4-/-
mice [32]. Dll1 is strongly induced in arterial endothelial
cells during ischemia-induced arteriogenesis, and Dll1+/-
mice display reduced collateral-artery growth and
impaired blood-flow recovery after hind-limb ischemia
[38]. Notch activation and ephrinB2 induction are not
observed in the collateral arteries of Dll1+/- mice [38].
Concluding remarks and future perspectives
Studies performed in the past few years clearly demon-
strate that the different Notch ligands have distinct func-
tions in vascular development and disease. This
understanding has prompted numerous investigations
into the mechanisms by which Notch signaling is essen-
tial for multiple aspects of vascular biology. However,
given that the effects of Notch pathway activation on
endothelial cells are context-dependent [4], many ques-
tions remain to be answered. First, the upstream signaling
pathways that control the expression of Notch ligands in
blood vessels remain largely unknown; VEGF induces
Dll4 expression in endothelial cells (Table 1), but Jagged1
is absent in tip cells where Dll4 is highly expressed, which
suggests that the two ligands are regulated differently. Sec-
ond, the selective activation of Notch in vascular endothe-
lium remains unclear; for example, Notch signaling is not
activated in arteries of Dll1 mutant mice, despite the pres-
ence of Jagged1 and Dll4 [19]. Third, the role of non-
canonical Notch ligands, such as microfibril-associated
glycoprotein (MAGP)-2 [9], is poorly understood. MAGP-
2 binds to Jagged1, Jagged2, Dll1, and Notch1 [61,62],
and is known to modulate Notch signaling in sprouting
angiogenesis [63,64], but the mechanistic basis for the
function of MAGP-2 in ligand-dependent Notch activa-
tion has yet to be elucidated. Finally, given that Dll4 and
Jagged1 have opposing effects on angiogenesis, experi-
ments that specifically inhibit each ligand with selectiveJournal of Angiogenesis Research 2009, 1:8 http://www.jangiogenesis.com/content/1/1/8
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neutralizing antibodies [65] may be important not only
for understanding how Notch is activated in the vascula-
ture, but also for the development of therapeutic strategies
designed to control angiogenesis by targeting Notch sign-
aling.
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